Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had revenue of $195.98K in the twelve months ending March 31, 2024, with 38.08% growth year-over-year. In the year 2023, Inhibikase Therapeutics had annual revenue of $260.50K with 111.03% growth.

• Revenue (ttm): $195.98K
• Revenue Growth: +38.08%
• P/S Ratio: 57.01
• Revenue / Employee: $24,498
• Employees: 8
• Market Cap: 11.17M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	260.50K	137.06K	111.03%
Dec 31, 2022	123.44K	-2.98M	-96.02%
Dec 31, 2021	3.10M	2.40M	343.92%
Dec 31, 2020	698.47K	-424.27K	-37.79%
Dec 31, 2019	1.12M	-2.92M	-72.22%
Dec 31, 2018	4.04M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.